Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Abstract
Patients with resected, local–regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint blockade (ICB) has demonstrated clinical activity, but biomarkers of response and effect on survival remain unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 28, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-3351
Entities
People
- Alice Tang
- Ann M. Gillenwater
- Benjamin H. Hinrichs
- Casey L. Allen
- Chad Zender
- Diana Bell
- Francis P. Worden
- J. Jack Lee
- John M. Kaczmar
- Jonathan Mark
- Keith Casper
- Maria Mathews
- Mario Medvedovic
- Matthew O. Old
- Maura L. Gillison
- Michelle L. Mierzwa
- Muhammed Kashif Riaz
- Neal E. Dunlap
- Nicky Kurtzweil
- Nusrat Harun
- Roman Jandarov
- Sarah Palackdharry
- Shuchi Gulati
- Trisha M Wise-Draper
- Vinita Takiar
- Yash Patil
Organizations
- American Cancer Society
- Eastern Virginia Medical School
- Medical University of South Carolina
- National Institutes of Health
- Ohio State University
- United States Department of Defense
- United States Department of Veterans Affairs
- University of Cincinnati
- University of Louisville
- University of Michigan
- University of Texas at Austin